Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

treatment

treatment is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 407
News articles 0
Drug details — treatment
Class
—
Route
—
Patents
20
Programs
407
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

treatment is an FDA-listed pharmaceutical active ingredient.

Key facts

INN treatment

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. 040201 Phase 3 · Takeda · Hemophilia A
  2. 160902 Phase 3 · Takeda · Primary Immunodeficiency Diseases (PID)
  3. 2.16/VI/22 Phase 3 · Cardiol Therapeutics · Patients with functionally single ventricle (FSV - functiona
  4. 20186 Phase 3 · Bayer · Treatment of children with chronic kidney disease and protei
  5. 2021/3336 Phase 3 · George Institute for · Maintenance treatment in metastatic non-squamous lung cancer
  6. 2023/3720 UMBRELLA Phase 3 · George Institute for · patients with a positive status for molecular residual disea
  7. 20230127 Phase 3 · Amgen · Early-stage Non-squamous Non-small Cell Lung Cancer
  8. 2024/4031 Phase 3 · George Institute for · Patients with primary HPV high-grade squamous intra-epitheli

Related patents

Browse patents

  1. US 20260146049

    SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER

    Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 20260097057

    COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS

    Expires Wed Apr 04 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 20260083736

    GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDER IN PATIENTS WITH HIGH IMPULSIVITY

    Expires Wed Mar 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 20260060930

    New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases

    Expires Wed Feb 28 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 20260034134

    TREATMENT OF CANCER WITH METASTASES IN THE CENTRAL NERVOUS SYSTEM

    Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12533358

    Methods of treatment with elinzanetant

    Expires Mon Jan 22 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 2025388678

    Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer

    Expires Wed Dec 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. AU 2025242171

    A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders

    Expires Wed Dec 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. AU 2024276234

    METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES

    Expires Wed Nov 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 2025325692

    METHODS OF TREATMENT USING ANTI-SEZ6 ANTIBODY DRUG CONJUGATES

    Expires Wed Oct 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12427160

    Use of cannabinoids in the treatment of epilepsy

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12421282

    Compositions and methods for the treatment of metabolic and liver disorders

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12415843

    Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12414995

    Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12414963

    Treatment of sleep-wake disorders and neurodegenerative disease comprising modified resistant maltodextrin

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 2025281584

    ACTIVE VACCINATION FOR THE TREATMENT OF NGF-RELATED DISORDERS

    Expires Wed Sep 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12409205

    Nanomolecules for the treatment of inflammatory bowel diseases

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12409224

    Compositions and methods for the treatment of VEN/AZA resistant acute myeloid leukemia

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12409181

    Treatment for aortic aneurysms

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is treatment?

treatment is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.